During this decade the company marketed a number of products within various therapeutic fields, including cardiology, epilepsy and hypertension.
This period also saw significant growth in the firm’s magnetic resonance portfolio.
Juste co-promoted oral contraceptives and launched an EFP (advertised pharmaceutical speciality) indicated for menopause symptoms.
Creation of Juste Biotech to carry out R&D in genomic and proteomic diagnostic methods for complex diseases.
Juste’s Hospitals Unit reinforced with new launches in the oncology and intensive care fields.